Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Czajkowsky, Daniel M ^a   Andersen, Jan Terje ^b   Fuchs, Anja ^c   Wilson, Timothy J ^c   Mekhaiel, David ^d   Colonna, Marco ^c   He, Jianfeng ^a   Shao, Zhifeng ^a   Mitchell, Daniel A ^e   Wu, Gang ^f   Dell, Anne ^f   Haslam, Stuart ^f   Lloyd, Katy A ^d   Moore, Shona C ^d   Sandlie, Inger ^b,g   Blundell, Patricia A ^d   Pleass, Richard J ^d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FC RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PROTEIN BINDING; VACCINE;

BIOMIMETICS; CELL CULTURE; HALF LIFE TIME; HUMAN; IMMUNOLOGY; MONONUCLEAR CELL; PROCEDURES;

BIOMIMETICS; CARRIER PROTEINS; CELLS, CULTURED; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; PROTEIN BINDING; RECEPTORS, FC; VACCINES;

EID: 84928720479     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09526     Document Type: Article

References (66)

1. Czajkowsky, D. M., Hu, J., Shao, Z. & Pleass, R. J. Fc-fusion proteins: new developments and future perspectives. EMBO. Mol. Med. 4, 1015-1028 (2012).
2. Aggarwal, R. S. What's fueling the biotech engine-2012 to 2013. Nat. Biotech. 32, 32-39 (2014).
3. Ye, L., Zeng, R., Bai, Y., Roopenian, D. C. & Zhu, X. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat. Biotech. 29, 158-163 (2011).
4. Jain, A. et al. Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res. Thera. 14, R192 (2012).
5. Daeron, M., Malbec, O., Latour, S., Arock, M. & Fridman, W. H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J. Clin. Invest. 95, 577-585 (1995).
6. Wilson, T. J., Fuchs, A. & Colonna, M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J. Immunol. 188, 4741-4745 (2012).
7. Su, K. et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178, 3272-3280 (2007).
8. Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
9. Sondermann, P., Pincetic, A., Maamary, J., Lammens, K. & Ravetch, J. V. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. USA. 110, 9868-9872 (2013).
10. Yu, X., Vasiljevic, S., Mitchell, D. A., Crispin, M. & Scanlan, C. N. Dissecting the Molecular Mechanism of IVIg Therapy: The Interaction between Serum IgG and DC-SIGN is Independent of Antibody Glycoform or Fc Domain. J. Mol. Biol. 425, 1253-1258 (2013).
11. Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475, 110-113 (2011).
12. Crispin, M., Yu, X. & Bowden, T. A. Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc. Natl. Acad. Sci. USA. 110, E3544-3546 (2013).
13. Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176-189 (2013).
14. Campbell, J. A. et al. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin. J. Immunol. 185, 28-32 (2010).
15. Londrigan, S. L. et al. N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or LSIGN. J. Virol. 85, 2990-3000 (2011).
16. Mohan, J. et al. Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1. Blood 107, 4433-4439 (2006).
17. Capon, D. J. et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 337, 525-531 (1989).
18. Mekhaiel, D. N. et al. Polymeric human Fc-fusion proteins with modified effector functions. Sci. Rep. 1, 124 (2011).
19. Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260-1263 (2014).
20. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725 (2007).
21. Pincetic, A. et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707-716 (2014).
22. Franco, A. et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J. Immunol. 190, 5739-5746 (2013).
23. Rath, T. et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit. Rev. Biotech. (2013), October 24, doi:10.3109/07388551.2013.834293.
24. Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276, 6591-6604 (2001).
25. Raghavan, M., Bonagura, V. R., Morrison, S. L. & Bjorkman, P. J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34, 14649-14657 (1995).
26. Mitchell, D. A., Fadden, A. J. & Drickamer, K. Anovel mechanism of carbohydrate recognition by the C-type lectins DC-SIGNand DC-SIGNR. Subunit organization and binding to multivalent ligands. J. Biol. Chem 276, 28939-28945 (2001).
27. Becer, C. R. et al. High-affinity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN interactions with HIV envelope glycoprotein. J. Amer. Chem. Soc. 132, 15130-15132 (2010).
28. Samuelsson, A., Towers, T. L. & Ravetch, J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486 (2001).
29. Schwab, I., Biburger, M., Kronke, G., Schett, G. & Nimmerjahn, F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42, 826-830 (2012).
30. Goodfellow, J. J. et al. An endoglycosidase with alternative glycan specificity allows broadened glycoprotein remodelling. J. Amer. Chem. Soc. 134, 8030-8033 (2012).
31. Kurosaki, T., Gander, I. & Ravetch, J. V. A subunit common to an IgG Fc receptor and the T-cell receptor mediates assembly through different interactions. Proc. Natl. Acad. Sci. USA. 88, 3837-3841 (1991).
32. Lux, A., Yu, X., Scanlan, C. N. & Nimmerjahn, F. Impact of immune complex size and glycosylation on IgG binding to human Fcgamma Rs. J. Immunol. 190, 4315-4323 (2013).
33. Coloma, M. J., Clift, A., Wims, L. & Morrison, S. L. The role of carbohydrate in the assembly and function of polymeric IgG. Mol. Immunol. 37, 1081-1090 (2000).
34. Ido, S. et al. Immunoactive two-dimensional self-assembly of monoclonal antibodies in aqueous solution revealed by atomic force microscopy. Nat. Mat. 13, 264-270 (2014).
35. Davis, R. S. Fc receptor-like molecules. Ann. Rev. Immunol. 25, 525-560 (2007).
36. Lu, J., Ellsworth, J. L., Hamacher, N., Oak, S. W. & Sun, P. D. Crystal structure of Fcgamma receptor I and its implication in high affinity gamma-immunoglobulin binding. J. Biol. Chem. 286, 40608-40613 (2011).
37. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267-273 (2000).
38. Crispin, M. et al. Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. J. Mol. Biol. 387, 1061-1066 (2009).
39. Feinberg, H., Mitchell, D. A., Drickamer, K. & Weis, W. I. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294, 2163-2166 (2001).
40. Harris, L. J., Larson, S. B., Hasel, K. W. & McPherson, A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36, 1581-1597 (1997).
41. Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767-779 (2007).
42. Ehrhardt, G. R. et al. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc. Natl. Acad. Sci. USA. 100, 13489-13494 (2003).
43. Haga, C. L., Ehrhardt, G. R., Boohaker, R. J., Davis, R. S. & Cooper, M. D. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc. Natl. Acad. Sci. USA. 104, 9770-9775 (2007).
44. Woof, J. M. & Burton, D. R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4, 89-99 (2004).
45. Gringhuis, S. I., den Dunnen, J., Litjens, M., van der Vlist, M. & Geijtenbeek, T. B. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 10, 1081-1088 (2009).
46. Gringhuis, S. I. et al. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NFkappaB. Immunity 26, 605-616 (2007).
47. Leontyev, D. et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52, 1799-1805 (2012).
48. van Liempt, E. et al. Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS lett. 580, 6123-6131 (2006).
49. Carroll, M. C. & Isenman, D. E. Regulation of humoral immunity by complement. Immunity 37, 199-207 (2012).
50. Fearon, D. T. & Carroll, M. C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Ann. Rev. Immunol. 18, 393-422 (2000).
51. Oi, V. T. et al. Correlation between segmental flexibility and effector function of antibodies. Nature 307, 136-140 (1984).
52. Saphire, E. O. et al. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319, 9-18 (2002).
53. Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. & Parren, P. W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75, 12161-12168 (2001).
54. Baker, K. et al. Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. Immunity 39, 1095-1107 (2013).
55. Mi, W. et al. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments. J. Immunol. 181, 7550-7561 (2008).
56. Smith, R. I., Coloma, M. J. & Morrison, S. L. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol. 154, 2226-2236 (1995).
57. Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotech. 28, 157-159 (2010).
58. Hinton, P. R. et al. An engineered human IgG1 antibody with longer serum halflife. J. Immunol. 176, 346-356 (2006).
59. North, S. J. et al. Mass spectrometric analysis of mutant mice. Meths. Enzymol. 478, 27-77 (2010).
60. Ceroni, A. et al. Glyco Workbench: a tool for the computer-assisted annotation of mass spectra of glycans. J. Prot. Res. 7, 1650-1659 (2008).
61. Wilson, T. J., Gilfillan, S. & Colonna, M. Fc receptor-like A associates with intracellular IgG and IgM but is dispensable for antigen-specific immune responses. J. Immunol. 185, 2960-2967 (2010).
62. Guex, N. & Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723 (1997).
63. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. Phys. 79, 926-935 (1983).
64. Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802 (2005).
65. Best, R. B. et al. Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone phi, psi and Side-Chain chi (1) and chi(2) Dihedral Angles. J. Chem. Theory. Comput. 8, 3257-3273 (2012).
66. Jo, S., Song, K. C., Desaire, H., MacKerell, A. D. & Im, W. Glycan Reader: Automated Sugar Identification and Simulation Preparation for Carbohydrates and Glycoproteins. J. Comput. Chem. 32, 3135-3141 (2011).